Medifocus, Inc. (TSX:MFS)

[BioSpecialist]

Final PIII in Breast Cancer// Mcap 7 M$

This stock is definitely flying under Radar ..Get in now before the stock gets discovered ..

Medifocus will HIT 10$+ within 12-15 Months .

Medifocus

Market-Cap: 7 Mio $
Price: 0,28 $

Shares Out : 24,3 Mio


Medifocus, Inc. Announces That It Has Received Approval to Initiate Its Pivotal Phase III Clinical Trial for Treatment of Breast Cancer from the Food and Drug Administration (FDA), Investigational Device Exemption (IDE) Application
http://www.stockhouse.com/tools/?page=%2FFinancialTools%2Fsn_newsreleases.asp%3Fsymbol%3DV.MFS%26newsid%3D7657794


Medifocus, Inc. Announces Positive Clinical Results of Its Breast Cancer Treatment Studies Published in Annals of Surgical Oncology: Planning to Begin Phase III In Early 2010
1/12/2010 9:30:01 AM - Business Wire
http://www.stockhouse.com/tools/?page=%2FFinancialTools%2Fsn_newsreleases.asp%3Fsymbol%3DV.MFS%26newsid%3D7591353


Fact Sheet
http://www.medifocusinc.com/files/medifocus_fs_Oct2009.pdf


Homepage
http://www.medifocusinc.com/company.asp


Market Potential

It is projected that invasive breast cancer cases in the US will have increased to 213,000 new cases in 2006 (National Cancer Institute). This is expected to increase to 480,000 new cases a year by 2017. This market is growing dramatically as the North American population ages.

Management believes that Medifocus’ technology can be useful in the treatment of the entire range of breast cancers. The first indication, large breast cancers, represents 20% of the total incidence of breast cancer. Medifocus is initially targeting 20% of that market.

The Medifocus system will be the first-to-market with its APA solution in 2010 - 2011, when experts suggest that the rate of diagnosis of large breast tumors will reach 76,000.